Emerging markets sales were $2.6 billion, up 21.0 % from the prior year and representing 26.1 % of total product sales, with solid growth across all of Abbott’s operating divisions. The gross margin ratio was 60.4 % in the third quarter, above Abbott’s earlier guidance, driven by favorable item mix. Abbott is definitely confirming its assistance for double-digit ongoing earnings-per-share growth for 2011 and can be narrowing its previous assistance range. Abbott’s ongoing earnings-per-share guidance for full-12 months 2011 is definitely $4.64 to $4.66, excluding specified products, reflecting 11.5 % growth at the midpoint of the number. ‘Strong efficiency across our businesses allowed Abbott to continue to provide superior results,’ said Miles D. White, chairman and chief executive officer, Abbott.'s sales soaring last one fourth does the same for the expectations of an incredible number of patients. Sandra Cabrera and Ted Tabor both suffered devastating damage from hepatitis C. After just weeks of acquiring Gilead's Sovaldi, they feel better and exams suggest the lethal virus is disappearing from their blood . Related StoriesASTRO concerned about proposed Medicare physician payment cuts to radiation therapyMedicare sufferers in rural configurations have lower prices of post-discharge follow-up careCost of radiation therapy varies widely among Medicare patients with cancerKaiser Health Information: Capsules: Advocacy Groupings Say Medicare Should Negotiate With Drugmakers Costly new blockbuster drugs, such as a $1,000-a-tablet hepatitis C treatment called Sovaldi, highlight the need to soon do something, the California Democrat said, wednesday by two advocacy groups backing recommendations made in a report released, the Medicare Rights Middle and Social Security Works .